Literature DB >> 18463333

FDA approves pharmacologic stress agent.

Cheryl A Thompson.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18463333     DOI： 10.2146/news080038

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  10 in total

Review 1.  Ischemia and reperfusion--from mechanism to translation.

Authors:  Holger K Eltzschig; Tobias Eckle
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

2.  Quantification of myocardial perfusion in clinical trials.

Authors:  Mario Petretta; Carmela Nappi; Alberto Cuocolo
Journal:  J Nucl Cardiol       Date:  2015-04       Impact factor: 5.952

3.  The GS Protein-coupled A2a Adenosine Receptor Controls T Cell Help in the Germinal Center.

Authors:  Robert K Abbott; Murillo Silva; Jasmine Labuda; Molly Thayer; Derek W Cain; Phaethon Philbrook; Shalini Sethumadhavan; Stephen Hatfield; Akio Ohta; Michail Sitkovsky
Journal:  J Biol Chem       Date:  2016-12-14       Impact factor: 5.157

Review 4.  Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.

Authors:  Aviral Vij; Yasmeen Golzar; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2017-06-26       Impact factor: 5.952

5.  Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: rationale and design of a prospective, randomized, multicenter study.

Authors:  Furqan H Tejani; Randall C Thompson; Ami E Iskandrian; Bruce E McNutt; Billy Franks
Journal:  J Nucl Cardiol       Date:  2010-11-17       Impact factor: 5.952

6.  Signaling through hepatocellular A2B adenosine receptors dampens ischemia and reperfusion injury of the liver.

Authors:  Michael A Zimmerman; Almut Grenz; Eunyoung Tak; Maria Kaplan; Douglas Ridyard; Kelley S Brodsky; Mercedes Susan Mandell; Igal Kam; Holger K Eltzschig
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-28       Impact factor: 11.205

7.  A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.

Authors:  Karthik Ananthasubramaniam; Robert Weiss; Bruce McNutt; Barbara Klauke; Kathleen Feaheny; Stan Bukofzer
Journal:  J Nucl Cardiol       Date:  2012-01-19       Impact factor: 5.952

8.  Adenosine A2A Receptor Activation Enhances Blood-Tumor Barrier Permeability in a Rodent Glioma Model.

Authors:  Amélie Vézina; Monica Manglani; DreeAnna Morris; Brandon Foster; Matthew McCord; Hua Song; Meili Zhang; Dionne Davis; Wei Zhang; Jessica Bills; Kunio Nagashima; Priya Shankarappa; Jessica Kindrick; Stuart Walbridge; Cody J Peer; William D Figg; Mark R Gilbert; Dorian B McGavern; Leslie L Muldoon; Sadhana Jackson
Journal:  Mol Cancer Res       Date:  2021-09-14       Impact factor: 6.333

9.  Caffeine Consumption and Heart Rate and Blood Pressure Response to Regadenoson.

Authors:  Abbas Bitar; Ronald Mastouri; Rolf P Kreutz
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

Review 10.  Pharmacological Preconditioning by Adenosine A2a Receptor Stimulation: Features of the Protected Liver Cell Phenotype.

Authors:  Elisa Alchera; Chiara Imarisio; Giorgia Mandili; Simone Merlin; Bangalore R Chandrashekar; Francesco Novelli; Antonia Follenzi; Rita Carini
Journal:  Biomed Res Int       Date:  2015-10-11       Impact factor: 3.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.